Treatment of white coat HYpertension in the very elderly trial (HYVET 2) - Feasibility of a randomized controlled trial (study protocol)

TY - JOUR

T1 - Treatment of white coat HYpertension in the very elderly trial (HYVET 2) - Feasibility of a randomized controlled trial (study protocol)

AU - Okorie, Michael

AU - Ali, Khalid

AU - Bremner, Stephen

AU - Beckett, Nigel

AU - Jackson, Stephen

AU - Quirk, Richard

AU - McAlister, Colin

AU - Perry, Nicky

AU - Potter, John

AU - Bulpitt, Christopher

AU - Rajkumar, Chakravarthi

N1 - Publisher Copyright: © 2019 Association for Research into Arterial Structure and Physiology.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of benefit of the treatment of hypertension in those 80 years or older. Following a subsequent sub study analysis of the HYVET data there is a suggestion that 50% of patients in the main study had White Coat Hypertension (WCH), defined as clinic BP readings >140/90 mmHg and ambulatory BP readings <135/85 mmHg. Currently, definitive evidence in support of treatment for such individuals is not available. HYVET 2 has been designed in order to assess the feasibility of conducting a randomized controlled trial which might determine whether the treatment of WCH in the very elderly is clinically beneficial. One hundred participants aged ≥75 years diagnosed with WCH will be recruited from General Practices (GPs) in UK. Randomization will be 1:1 to a treatment arm (indapamide and perindopril) and control arm (no treatment) and follow up will be for 52 weeks. HYVET 2 will report on feasibility outcomes including participant recruitment, adherence and withdrawal rates, willingness of GPs to recruit and randomize patients and the frequency of a composite of cardiovascular events. Simple descriptive statistics will be presented.

AB - The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of benefit of the treatment of hypertension in those 80 years or older. Following a subsequent sub study analysis of the HYVET data there is a suggestion that 50% of patients in the main study had White Coat Hypertension (WCH), defined as clinic BP readings >140/90 mmHg and ambulatory BP readings <135/85 mmHg. Currently, definitive evidence in support of treatment for such individuals is not available. HYVET 2 has been designed in order to assess the feasibility of conducting a randomized controlled trial which might determine whether the treatment of WCH in the very elderly is clinically beneficial. One hundred participants aged ≥75 years diagnosed with WCH will be recruited from General Practices (GPs) in UK. Randomization will be 1:1 to a treatment arm (indapamide and perindopril) and control arm (no treatment) and follow up will be for 52 weeks. HYVET 2 will report on feasibility outcomes including participant recruitment, adherence and withdrawal rates, willingness of GPs to recruit and randomize patients and the frequency of a composite of cardiovascular events. Simple descriptive statistics will be presented.

KW - Feasibility study

KW - Treatment

KW - Very elderly

KW - White coat hypertension

UR - https://www.scopus.com/pages/publications/85081372624

U2 - 10.2991/artres.k.191106.001

DO - 10.2991/artres.k.191106.001

M3 - Article

AN - SCOPUS:85081372624

SN - 1872-9312

VL - 25

SP - 19

EP - 25

JO - Artery Research

JF - Artery Research

IS - 1-2

ER -